AI Innovation in the Biotech Industry: A New Turning Point in Drug Development and Personalized Medicine by 2026
Editor
In 2026, the biotechnology industry is entering an unprecedented era of innovation through its integration with artificial intelligence. The global AI-based drug development market is experiencing a rapid growth of 39.5%, increasing from $86 billion in 2025 to $120 billion in 2026, fundamentally altering the traditional drug development paradigm. Notably, investments in AI by major pharmaceutical companies have surged by 65% from the previous year, reaching $28 billion, significantly enhancing the speed and success rate of drug development. In Korea, the government is expanding its investment to 2.3 trillion won in 2026, centered around the K-Bio Belt project, thereby strengthening its competitiveness in the global biotech ecosystem.
The most remarkable achievement of AI-based drug development is the revolutionary reduction in development time. Unlike traditional drug development, which typically takes 10-15 years, AI-assisted drug development is shortened to 3-5 years, with clinical trial success rates more than doubling from 12% to 28%. The commercialization of DeepMind’s AlphaFold technology in Cambridge, UK, for protein structure prediction has significantly accelerated the process from target discovery to lead compound optimization. In fact, the number of AI-developed drug candidates entering Phase 3 clinical trials increased by 180% year-on-year to 47 cases from late 2025 to early 2026, raising industry expectations.
In the field of Precision Medicine, the influence of AI is rapidly expanding. As of 2026, the global precision medicine market has grown to $785 billion, with AI-based solutions accounting for 34%, or $267 billion. The increased use of AI in genomic analysis and biomarker discovery is making the development of treatments tailored to individual patients’ genetic characteristics a reality. The AI-based cancer diagnosis platform FoundationOne CDx, jointly developed by Foundation Medicine in Boston, USA, and Roche in Basel, Switzerland, is utilized in 2,400 medical institutions worldwide as of the end of 2025, processing an average of 150,000 genomic analyses per month.
AI Strategies and Market Competition Among Global Biotech Companies
Global pharmaceutical and biotech companies are accelerating investments and mergers and acquisitions to secure AI technology. Johnson & Johnson, headquartered in New Jersey, USA, invested $1.2 billion in AI biotech startup Numerate in 2025, and increased its AI R&D budget by 85% to $3.4 billion in 2026. Novartis in Basel, Switzerland, has established the AI-based drug development platform ‘Genesis’ through a partnership with Google DeepMind, currently developing 23 drug candidates simultaneously. Pfizer, headquartered in New York, USA, has expanded its collaboration with IBM Watson to fully integrate AI into cancer drug development, with six AI-based drug candidates entering clinical trials in the first half of 2026 alone.
Korean biotech companies are also standing out in global competition. Samsung Biologics in Incheon recorded sales of 3.12 trillion won in 2025, capturing a 17.3% share of the global CMO (Contract Manufacturing Organization) market. The introduction of AI-driven production optimization systems has improved production efficiency by 23%, and with the completion of its fourth plant in 2026, its annual production capacity is set to expand to 360,000 liters. Celltrion in Songdo, Incheon, has reduced the development period of biosimilars from 7-8 years to 4-5 years through its self-developed AI-based biosimilar development platform, currently holding 12 biosimilar candidates in its pipeline as of 2026.
As competition intensifies, companies are diversifying their differentiation strategies. SK Biopharm in Seongnam has established an AI drug development platform specialized in central nervous system disorders, investing 180 billion won annually in AI-based drug development following the success of its epilepsy treatment ‘Cenobamate’, approved by the FDA in 2025. The company began fully utilizing AI for Parkinson’s and Alzheimer’s drug development in 2026, showing significant results in early clinical trials, attracting industry attention. Meanwhile, global big pharma companies are opting for strategic partnerships with platform companies to secure AI capabilities.
Market analysts predict that the growth momentum in the AI biotech sector will continue. According to McKinsey’s 2026 biotech report, the AI-based drug development market is expected to grow at an annual average rate of 32%, reaching $420 billion by 2030. The Asia-Pacific region is anticipated to have the highest growth rate at 45% annually, with Korea, China, and Japan leading this growth. In terms of investment, AI-related investments accounted for 42%, or $18.7 billion, of global biotech venture capital investments in 2025, with this proportion expected to exceed 50% in 2026.
Technological Innovation and Changes in the Regulatory Environment
The advancement of AI technology in the biotech industry is also accompanied by changes in the regulatory environment. The US FDA announced the ‘AI/ML-Based Medical Device and Drug Development Guidelines’ in December 2025 and is implementing a new regulatory framework from 2026 to ensure transparency and reproducibility in AI-based drug development processes. The European Medicines Agency (EMA) also introduced the ‘Fast Track AI’ program in February 2026 to streamline the clinical trial approval process for AI-based drug development, reducing the approval period from 18 months to 12 months. The Korean Ministry of Food and Drug Safety plans to implement the ‘AI Drug Development Regulatory Sandbox’ system from the second half of 2026 to provide regulatory flexibility for innovative AI-based drug development.
On the technical side, the application of generative AI and large language models (LLM) in the biotech field is accelerating. Genentech in San Francisco, California, has improved the accuracy of molecular structure design and drug-target interaction prediction to 87% using its self-developed ‘BioGPT’ model. This technology can derive drug candidates 100 times faster than traditional computer-aided drug design (CADD) methods, revolutionizing the early stages of drug development. The combination of quantum computing and AI is also gaining attention, with the quantum-AI hybrid platform developed through the collaboration of IBM and Roche solving complex protein folding problems 1,000 times faster than before.
Data integration and interoperability are also emerging as important technological trends. As of 2026, there are 280 million biological sample data stored in biobanks worldwide, with standardization efforts underway to utilize them for AI learning. The UK Biobank, the US All of Us Research Program, and Korea’s Korean Genome and Epidemiology Study (KoGES) have formed the ‘Global Genomic AI Alliance’, opening integrated datasets for AI research from June 2026. The use of such large-scale datasets is expected to significantly improve the accuracy and generalization performance of AI models.
However, there are challenges to be addressed alongside technological advancements. Data privacy and security issues are major concerns, with several data breaches in biotech companies in the second half of 2025 leading to a surge in security investments across the industry. On average, biotech companies’ cybersecurity budgets increased by 78% from the previous year, with the adoption of ‘Federated Learning’ technology to protect AI models spreading. The issue of AI model bias is also emerging as a significant concern, with reports of drugs developed using biased training data being less effective in certain population groups, highlighting the need for AI development that considers diversity.
The AI innovation in the biotech industry is expected to accelerate further from 2026. As technological maturity increases, practical outcomes are becoming visible, and the regulatory environment is being refined, clarifying the commercialization path. With the strengthening of global competitiveness among Korean biotech companies, the growth potential of the domestic biotech ecosystem is gaining significant attention. Investors are continuously increasing their interest in biotech companies with AI capabilities, which is expected to be a key driver of industry growth in the coming years. However, it is also crucial to closely monitor technological challenges, regulatory uncertainties, and high development costs as risk factors.
*This article is for informational purposes only and does not constitute investment advice or recommendations. Investment decisions should be made based on individual judgment and responsibility.*
